Connect with UsInvestorsCareersMediaScienceContact UsHome News Biopharma Leaders Unite to Stand with Science Learn MorePfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19Learn MorePfizer Invests $120mil in Biotech InnovationLearn MorePfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 Learn MoreAgreement Reached with Covax for Advance Purchase of Covid-19 VaccineLearn MoreRecent Press Releases05.05.2021Pfizer Reports Strong First-quarter 2021 Results04.28.2021Pfizer Acquires Amplyx Pharmaceuticals04.22.2021Pfizer Declares Second-Quarter 2021 Dividend03.08.2021Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate03.04.2021Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference03.03.2021U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer02.26.2021European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older02.26.2021EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency02.25.2021Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants02.23.2021U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)02.22.2021Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference02.19.2021Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA02.17.2021Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids02.17.2021Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women02.17.2021Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma02.17.2021Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®02.17.2021In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer- BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations02.12.2021U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)02.12.2021Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine02.09.2021Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries02.05.2021Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 202702.02.2021Pfizer Reports Fourth-quarter and Full-year 2020 Results and Releases 5-year Pipeline Metrics01.27.2021Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)01.27.2021In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants01.26.2021Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis01.25.2021European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma01.22.2021Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-1901.20.2021Pfizer and BioNTech Publish of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture01.14.2021Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults01.12.2021Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative01.08.2021An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission01.07.2021Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy01.05.2021Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference01.04.2021US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency12.29.2020Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®12.28.2020LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA12.28.2020Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health12.23.2020Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine12.22.2020Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts12.21.2020Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine12.21.2020Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine12.14.2020Pfizer and BioNTech to Supply Singapore with their BNT162b2 mRNA-based Vaccine Candidate to Combat COVID-1912.14.2020Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b212.12.2020U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older12.12.2020Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-1912.11.2020BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma12.11.2020Pfizer Declares First-Quarter 2021 Dividend12.10.2020Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.12.10.2020Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine12.08.2020U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older12.07.2020Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma12.07.2020Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy11.23.2020Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors11.20.2020Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine11.19.2020Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine11.18.2020Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints11.16.2020Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan11.12.2020Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg11.11.2020Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference11.11.2020Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens11.11.2020Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-211.06.2020Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)11.05.2020Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock10.30.2020Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn10.27.2020FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis10.27.2020Pfizer Reports Third-quarter 2020 Results10.27.2020Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 202010.09.2020PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint10.08.2020Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency10.07.2020Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment10.06.2020BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b210.01.2020Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy09.28.2020U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis09.24.2020Pfizer Declares Fourth-Quarter 2020 Dividend09.23.2020FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma09.22.2020Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts09.18.2020Pfizer to Present Latest Scientific Advancements from Its Industry- Leading Portfolio at the ESMO Virtual Congress 202009.18.2020BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine09.15.2020Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas09.14.2020Pfizer Hosts Virtual Investor Day09.12.2020Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial09.11.2020Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference09.10.2020Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 202009.09.2020Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-1909.09.2020Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-209.08.2020Biopharma Leaders Unite To Stand With Science09.03.2020Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 202008.21.2020Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-1908.07.2020Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-1908.06.2020Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 202008.05.2020LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer08.05.2020Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate07.31.2020Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate07.28.2020Pfizer Reports Second-Quarter 2020 Results07.27.2020Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study07.22.2020Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-207.20.2020Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data07.20.2020Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-207.13.2020Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-207.09.2020Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance07.06.2020Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations across Asia Pacific07.01.2020Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-206.30.2020FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma06.30.2020European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)06.25.2020Pfizer Declares Third-Quarter 2020 Dividend06.24.2020Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa06.22.2020European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma06.22.2020Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines06.18.2020Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy06.18.2020Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn06.16.2020Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts06.12.2020Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th06.11.2020FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)06.10.2020Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis06.03.2020Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology06.02.2020Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference06.02.2020Pfizer Establishes New Program to Support Continued Biotechnology Innovation05.29.2020Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer05.29.2020Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer05.22.2020Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC05.19.2020Pfizer Prices $4,000,000,000 Debt Offering05.15.2020Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study05.14.2020Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age05.13.2020Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day05.12.2020New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program05.12.2020Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference05.08.2020Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting05.05.2020Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program05.04.2020New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized05.01.2020Pfizer Receives Positive CHMP Opinion for DAURISMO®(glasdegib)for Certain Adult Patients with Newly Diagnosed or Secondary Acute Myeloid Leukemia (AML)04.30.2020Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA1504.29.2020BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany04.28.2020Pfizer Reports First-Quarter 2020 Results04.23.2020Pfizer Hosts Virtual-Only Annual Meeting of Shareholders04.22.2020BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates04.09.2020Pfizer Advances Battle Against COVID-19 on Multiple Fronts04.09.2020Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development04.09.2020EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma04.08.2020EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma04.08.2020U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy04.07.2020Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders04.06.2020Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic04.02.2020Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors04.02.2020Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)04.01.2020Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic03.27.2020Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact03.26.2020Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn03.24.2020U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis03.18.2020Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older03.18.2020Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch03.18.2020Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns03.17.2020Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine03.13.2020EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study03.13.2020Pfizer Outlines Five-Point Plan to Battle COVID-1903.04.2020Susan Hockfield Elected to Pfizer’s Board of Directors03.02.2020U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis02.27.2020James Quincey Elected to Pfizer’s Board of Directors02.27.2020Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer02.27.2020Mylan and Pfizer Finalize Appointments to Viatris Board of Directors02.25.2020Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference02.18.2020European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)02.11.2020XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC01.31.2020Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)01.28.2020Pfizer Reports Fourth-quarter and Full-year 2019 Results01.23.2020Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults01.23.2020Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only Fda-approved Authorized Generic Version of Viagra® (sildenafil Citrate)01.06.2020BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Our PurposeOur ScienceOur ProductsCareersHealthcare ProfessionalsNewsContact UsPrivacy PolicyTerms of UseCopyright © 2011-2022 Pfizer Pte Ltd. All rights reserved. PP-UNP-SGP-0052